ONCOCYTE CORP's ticker is OCX and the CUSIP is 68235C107. A total of 97 filers reported holding ONCOCYTE CORP in Q3 2021. The put-call ratio across all filers is 0.14 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $4,531 | -40.5% | 19,700 | -8.4% | 0.00% | – |
| Q1 2023 | $7,619 | -94.4% | 21,500 | -94.9% | 0.00% | -100.0% |
| Q4 2022 | $136,029 | -75.1% | 423,900 | -43.5% | 0.00% | -80.0% |
| Q3 2022 | $547,000 | -36.5% | 749,700 | -21.7% | 0.01% | -37.5% |
| Q2 2022 | $862,000 | -42.8% | 957,400 | -5.3% | 0.01% | -42.9% |
| Q1 2022 | $1,506,000 | -32.7% | 1,010,700 | -2.0% | 0.01% | -30.0% |
| Q4 2021 | $2,238,000 | -50.5% | 1,031,500 | -18.8% | 0.02% | -57.4% |
| Q3 2021 | $4,524,000 | -43.3% | 1,270,967 | -8.5% | 0.05% | -44.7% |
| Q2 2021 | $7,973,000 | -5.3% | 1,389,006 | -14.4% | 0.08% | -17.5% |
| Q1 2021 | $8,423,000 | +2670.7% | 1,622,824 | +1173.8% | 0.10% | +2475.0% |
| Q4 2020 | $304,000 | -35.9% | 127,400 | -33.1% | 0.00% | -76.5% |
| Q2 2019 | $474,000 | -86.2% | 190,500 | -78.1% | 0.02% | -85.7% |
| Q1 2019 | $3,431,000 | – | 868,793 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BROADWOOD CAPITAL INC | 23,353,697 | $17,048,000 | 1.30% |
| AWM Investment Company, Inc. | 7,746,557 | $5,655,000 | 0.86% |
| PURA VIDA INVESTMENTS, LLC | 18,056,274 | $13,181,000 | 0.76% |
| Defender Capital, LLC. | 2,551,980 | $1,883,000 | 0.74% |
| Penbrook Management LLC | 563,350 | $411,000 | 0.35% |
| ACT CAPITAL MANAGEMENT, LLC | 330,000 | $241,000 | 0.33% |
| CALIBER WEALTH MANAGEMENT, LLC | 75,120 | $55,000 | 0.04% |
| Fort Sheridan Advisors LLC | 135,000 | $99,000 | 0.03% |
| Orbimed Advisors | 1,882,768 | $1,374,000 | 0.03% |
| WEALTH EFFECTS LLC | 51,000 | $37,000 | 0.02% |